|
|
| Line 1: |
Line 1: |
| <small>'''''Synonyms / Brand Names:''''' Avalide, Avapro, Irbesarran, Lrbesartan</small>
| | __NOTOC__ |
| | {{Irbesartan}} |
| | {{CMG}}; {{AE}} {{SS}} |
|
| |
|
| {{CMG}}
| | '''''For patient information about Irbesartan, click [[Irbesartan (patient information)|here]].''''' |
|
| |
|
| ==Dosing and Administration==
| | {{SB}} AVAPRO<sup>®</sup> |
| *'''Hypertension:''' The recommended initial dose of Avapro (irbesartan) is 150 mg once daily. Patients requiring further reduction in blood pressure should be titrated to 300 mg once daily.
| |
| *'''Nephropathy in type 2 diabetic patients:''' The recommended target maintenance dose is 300 mg once daily.
| |
| *'''Volume- and salt-depleted patients:''' A lower initial dose of Avapro (75 mg) is recommended in patients with depletion of intravascular volume or salt (eg, patients treated vigorously with diuretics or on hemodialysis).
| |
| ----
| |
| <br>
| |
| <font size="4">
| |
| [[{{PAGENAME}}#FDA Package Insert Resources|FDA Package Insert Resources]]
| |
| <br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br>
| |
| <br>
| |
| [http://www.pace-med-apps.com/gfrcalc.htm Calculate Creatine Clearance]
| |
| <br></font size><small>On line calculator of your patients Cr Cl by a variety of formulas.</small><font size="4"><br>
| |
| <br>
| |
| [http://home.earthlink.net/~sensei11/convert.htm Convert pounds to Kilograms]
| |
| <br></font size><small>On line calculator of your patients weight in pounds to Kg for dosing estimates.</small><font size="4"><br>
| |
| <br> [[{{PAGENAME}}#Publication Resources|Publication Resources]]
| |
| <br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#Trial Resources|Trial Resources]]
| |
| <br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#Guidelines & Evidence Based Medicine Resources|Guidelines & Evidence Based Medicine Resources]]
| |
| <br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#Media Resources|Media Resources]]
| |
| <br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br><br> | |
| [[{{PAGENAME}}#Patient Resources|Patient Resources]]
| |
| <br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#International Resources|International Resources]]
| |
| <br></font size><small>en Español</small><font size="4"><br>
| |
| <br>
| |
| ----
| |
| <br>
| |
| <br>
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==FDA Package Insert Resources== | | ==Overview== |
| [[{{PAGENAME}} indications|Indications]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} contraindications|Contraindications]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} side effects|Side Effects]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} drug interactions|Drug Interactions]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} precautions|Precautions]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} overdose|Overdose]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} instructions for administration|Instructions for Administration]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} how supplied|How Supplied]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} pharmacokinetics and molecular data|Pharmacokinetics and Molecular Data]]
| |
| <br>
| |
| <br>
| |
| [http://www.fda.gov/cder/foi/label/2006/020757s038lbl.pdf FDA label]
| |
| <br>
| |
| <br>
| |
| [http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Publication Resources==
| | '''Irbesartan''' ([[International Nonproprietary Name|INN]]) {{IPAc-en|ɜr|b|ə|ˈ|s|ɑr|t|ən}} is an [[angiotensin II receptor antagonist]] used mainly for the treatment of [[hypertension]]. Irbesartan was developed by Sanofi Research (now part of [[sanofi-aventis]]). It is jointly marketed by [[sanofi-aventis]] and [[Bristol-Myers Squibb]] under the [[trade name]]s '''Aprovel''', '''Karvea''', and '''Avapro'''. |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most Recent Articles on {{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}] | |
| <br>
| |
| <br>
| |
| [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D Review Articles on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28%28N+Engl+J+Med%5Bta%5D%29+OR+%28Lancet%5Bta%5D%29+OR+%28BMJ%5Bta%5D%29%29 Articles on {{PAGENAME}} in N Eng J Med, Lancet, BMJ] | |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} detailed information|WikiDoc State of the Art Review]] | |
| <br>
| |
| <br>
| |
| [http://books.google.com/books?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=gp Textbook Information on {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Trial Resources== | | ==Category== |
| [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials with {{PAGENAME}} at Clinical Trials.gov]
| | Angiotensin II receptor antagonists;Sanofi;Bristol-Myers Squibb;Tetrazoles;Biphenyls;Lactams;Spiro compounds;Nitrogen heterocycles;Cardiovascular Drugs |
| <br>
| | ==FDA Package Insert== |
| <br>
| |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28randomized+controlled+trial%5BPublication+Type%5D+OR+%28randomized%5BTitle%2FAbstract%5D+AND+controlled%5BTitle%2FAbstract%5D+AND+trial%5BTitle%2FAbstract%5D%29%29 Trial Results with {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Guidelines & Evidence Based Medicine Resources==
| | ''' [[Irbesartan indications and usage|Indications and Usage]]''' |
| [http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse on {{PAGENAME}}] | | '''| [[Irbesartan dosage and administration|Dosage and Administration]]''' |
| <br>
| | '''| [[Irbesartan dosage forms and strengths|Dosage Forms and Strengths]]''' |
| <br>
| | '''| [[Irbesartan contraindications|Contraindications]]''' |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cochrane Database Syst Rev[ta])}} Cochrane Collaboration on {{PAGENAME}}] | | '''| [[Irbesartan warnings and precautions|Warnings and Precautions]]''' |
| <br>
| | '''| [[Irbesartan adverse reactions|Adverse Reactions]]''' |
| <br>
| | '''| [[Irbesartan drug interactions|Drug Interactions]]''' |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cost effectiveness)}} Cost Effectiveness of {{PAGENAME}}] | | '''| [[Irbesartan use in specific populations|Use in Specific Populations]]''' |
| <br>
| | '''| [[Irbesartan overdosage|Overdosage]]''' |
| <br>
| | '''| [[Irbesartan description|Description]]''' |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| | '''| [[Irbesartan clinical pharmacology|Clinical Pharmacology]]''' |
| <br>
| | '''| [[Irbesartan nonclinical toxicology|Nonclinical Toxicology]]''' |
| <br>
| | '''| [[Irbesartan clinical studies|Clinical Studies]]''' |
| ==Media Resources==
| | '''| [[Irbesartan how supplied storage and handling|How Supplied/Storage and Handling]]''' |
| [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint Slides on {{PAGENAME}}] | | '''| [[Irbesartan patient counseling information|Patient Counseling Information]]''' |
| <br>
| | '''| [[Irbesartan labels and packages|Labels and Packages]]''' |
| <br>
| |
| [http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images of {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=hPo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+podcasts+OR+MP3&btnG=Search Podcasts & MP3s on {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| [http://video.google.com/videosearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&um=1&sa=N&tab=fv# Videos on {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Patient Resources== | | ==Mechanism of Action== |
| [[{{PAGENAME}} (patient information)|Patient Information from National Library of Medicine]]
| |
| <br>
| |
| <br>
| |
| [http://www.google.com/search?hl=en&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:for_patients&cx=disease_for_patients&sa=N&oi=cooptsr&resnum=0&ct=col3&cd=1 Patient Resources on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://groups.google.com/groups/search?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search Discussion Groups on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:patient_handouts&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col1&cd=3 Patient Handouts on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the News]
| |
| <br>
| |
| <br>
| |
| [http://finance.google.com/finance?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=te {{PAGENAME}} in the Marketplace]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==International Resources== | | Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor. There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. |
| [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+en+espanol&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a {{PAGENAME}} en Español]
| | |
| <br>
| | Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. |
| <br>
| | |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| | Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure. |
| <br>
| | |
| <br>
| | Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known. |
| </font size>
| | |
| ----
| | ==References== |
| {{FDA}}
| | |
| | {{Reflist|2}} |
| | |
| | {{Angiotensin II receptor antagonists}} |
| | |
| | [[Category:Angiotensin II receptor antagonists]] |
| | |
| | [[Category:Bristol-Myers Squibb]] |
| | |
| | [[Category:Tetrazoles]] |
| | |
| | [[Category:Lactams]] |
| | |
| | [[Category:Nitrogen heterocycles]] |
| | |
| | [[Category:Cardiovascular Drugs]] |
|
| |
|
| [[Category:Drugs]] | | [[Category:Drugs]] |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Irbesartan, click here.
Synonyms / Brand Names: AVAPRO®
Overview
Irbesartan (INN) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
Category
Angiotensin II receptor antagonists;Sanofi;Bristol-Myers Squibb;Tetrazoles;Biphenyls;Lactams;Spiro compounds;Nitrogen heterocycles;Cardiovascular Drugs
FDA Package Insert
Indications and Usage
| Dosage and Administration
| Dosage Forms and Strengths
| Contraindications
| Warnings and Precautions
| Adverse Reactions
| Drug Interactions
| Use in Specific Populations
| Overdosage
| Description
| Clinical Pharmacology
| Nonclinical Toxicology
| Clinical Studies
| How Supplied/Storage and Handling
| Patient Counseling Information
| Labels and Packages
Mechanism of Action
Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor. There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.
Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.
Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure.
Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.
References
Template:Angiotensin II receptor antagonists